fuchs endothelial corneal dystrophy fecd market insight

DelveInsight’s ‘Fuchs Endothelial Corneal Dystrophy (FECD) —Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy (FECD), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Fuchs Endothelial Corneal Dystrophy (FECD) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Fuchs Endothelial Corneal Dystrophy (FECD) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Fuchs Endothelial Corneal Dystrophy (FECD) Disease Understanding and Treatment Algorithm

Fuchs Endothelial Corneal Dystrophy (FECD) Overview

Fuchs Endothelial Corneal Dystrophy (FECD) or Fuchs’ endothelial dystrophy is a defect of the cornea of the eye, where endothelial cells degenerate/get damaged. It can be either sporadic or inherited in an autosomal dominant manner. Fuchs’ dystrophy is characterized by the swelling of the cornea, which leads to glare, halo, and reduced visual acuity. In some cases, it can lead to corneal blindness.

 

FECD is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients and is more prominent in females than males. Deposits called guttae are generally detectable during an eye exam. They usually form in the middle of the cornea and eventually spread throughout the cornea. These guttae contribute to the ongoing cell death within the cornea, leading to worsening vision problems. Tiny blisters may develop on the cornea, which can burst and cause eye pain.

 

Fuchs Endothelial Corneal Dystrophy (FECD) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Fuchs Endothelial Corneal Dystrophy (FECD) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Fuchs Endothelial Corneal Dystrophy (FECD) market report thoroughly understands Fuchs Endothelial Corneal Dystrophy (FECD) symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Fuchs Endothelial Corneal Dystrophy (FECD) treatment algorithms and treatment guidelines for Fuchs Endothelial Corneal Dystrophy (FECD) symptoms in the US, Europe, and Japan.

 

There are no FDA-approved pharmacological therapies available for Fuchs Endothelial Corneal Dystrophy (FECD). While symptomatic treatments are used in the early stages, surgical intervention is required for advanced cases. If one has a severe form of the disease, minimally invasive lamellar endothelial keratoplasty (EK) procedures can be used. Penetrating keratoplasty, or a full-thickness corneal transplant, was the most dominant procedure for visually significant Fuchs’ dystrophy patients. However, this procedure is being replaced by a new set of procedures like Descemet’s stripping automated endothelial keratoplasty (DSAEK), Descemet’s membrane endothelial keratoplasty (DMEK), and Descemetorhexis without endothelial keratoplasty (DWEK). As donor cornea might be rejected after the transplant, patients are advised to apply topical steroids for the rest of their lives to dampen their immune response and prevent rejection of the transplanted cells. Dexamethasone is a type of corticosteroid medication that is commonly used. At present, medical interventions are adjuvant to surgeries.

 

Descemet’s stripping only (DSO) technique, which does not require donor cornea, has been combined with the topical use of a ROCK inhibitor to speed up recovery and increase endothelial cell density than happens with DSO alone. Rhopressa is used as an off-label usage for Fuchs endothelial corneal dystrophy.

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) is increasing 7MM during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology segmented as the prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD), Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD), and Age-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD). The report includes the prevalent scenario of Fuchs Endothelial Corneal Dystrophy (FECD)  symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The epidemiology segment also provides the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total number of prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) associated in 7MM countries was 17,386,186 in 2020, with a CAGR of 0.66%.

Fuchs Endothelial Corneal Dystrophy (FECD) Drug Chapters

The Fuchs Endothelial Corneal Dystrophy (FECD) report’s drug chapter segment encloses the detailed analysis of Fuchs Endothelial Corneal Dystrophy (FECD) early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Fuchs Endothelial Corneal Dystrophy (FECD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Fuchs Endothelial Corneal Dystrophy (FECD) Emerging Drug

 

Ripasudil Hydrochloride Hydrate: Kowa Pharmaceuticals

Ripasudil hydrochloride hydrate (brand name: Glanatec ophthalmic solution 0.4%; Kowa Company, Ltd., Japan) is a Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor that lowers IOP by increasing conventional aqueous outflow.

 

Rho kinase (ROCK) inhibitors lower IOP by a unique mechanism, namely the depolymerization of intracellular actin in the conventional outflow tissues: the trabecular meshwork (TM) and Schlemm’s canal (SC). Furthermore, ROCK inhibitors suppress the production of extracellular matrix by TM cells, which represents a potential alternative method of lowering IOP.

 

TTHX1114: Trefoil Therapeutics

Trefoil was founded to bring forward novel engineered FGF-1 (eFGF-1) compounds to treat corneal diseases and disorders. Lead candidate TTHX1114 is an engineered form of FGF-1 designed to protect corneal endothelial cells and restore vision loss by stimulating cell proliferation and migration. Trefoil’s first development program is being developed as an intracameral injection to potentially offer the first pharmacologic treatment for a “back of the cornea” surface disease (endothelial dystrophy), the leading cause of cornea transplantation.

Products detail in the report…

Fuchs Endothelial Corneal Dystrophy (FECD) Market Outlook

The report’s Fuchs Endothelial Corneal Dystrophy (FECD)  market outlook helps build a detailed comprehension of the historic, current, and forecasted Fuchs Endothelial Corneal Dystrophy (FECD)  market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 

This segment gives a thorough detail of Fuchs Endothelial Corneal Dystrophy (FECD)  market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the Fuchs Endothelial Corneal Dystrophy (FECD) market in 7MM is expected to grow in the study period 2018–2030.

 

Medical management of early Fuchs dystrophy is limited to decreasing corneal edema with topical hypertonic saline drops or ointment to shorten morning edema. Patients may use the ointment at bedtime and/or the drops upon awakening, typically one drop every 5 min for a total of 3–4 drops; however, this treatment does not change the course of the disease. Patients do note stinging with these agents, which reduces acceptance. Also, a hairdryer held 5–10 inches from the cornea may be used to facilitate corneal deturgescence. As the disease progresses, these interventions are no longer effective. Surgery is the preferred treatment once patients are symptomatic from their Fuchs Endothelial Corneal Dystrophy (FECD).

 

Key Findings

This section includes a glimpse of the Fuchs Endothelial Corneal Dystrophy (FECD) market in 7MM. Fuchs Endothelial Corneal Dystrophy (FECD) market size in the seven major markets was USD 34.7 million in 2020, and is expected to grow at CAGR of 33.05% during the study period.

 

The United States Market Outlook

This section provides the total Fuchs Endothelial Corneal Dystrophy (FECD) market size and market size by therapies in the United States.

 

The United States accounts for the largest market size of Fuchs Endothelial Corneal Dystrophy (FECD) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Fuchs Endothelial Corneal Dystrophy (FECD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Fuchs Endothelial Corneal Dystrophy (FECD) market Size and market Size by therapies in Japan are also mentioned.

Fuchs Endothelial Corneal Dystrophy (FECD) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Fuchs Endothelial Corneal Dystrophy (FECD) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Fuchs Endothelial Corneal Dystrophy (FECD) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Fuchs Endothelial Corneal Dystrophy (FECD) key players involved in developing targeted therapeutics.

 

Major players include Kowa Pharmaceuticals, Trefoil Therapeutics, ProQR Therapeutics and others.

 

Pipeline Development Activities

The report covers collaborations, acquisition, merger, licensing, and patent details for Fuchs Endothelial Corneal Dystrophy (FECD) emerging therapies.

Reimbursement Scenario in Fuchs Endothelial Corneal Dystrophy (FECD)

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

The high treatment costs affect patients’ affordability and access to treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.

 

The disease advocacy groups working in the area of disease helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Fuchs Endothelial Corneal Dystrophy (FECD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Fuchs Endothelial Corneal Dystrophy (FECD) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Fuchs Endothelial Corneal Dystrophy (FECD) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Fuchs Endothelial Corneal Dystrophy (FECD), explaining its causes, signs and symptoms, physiology, and currently available therapies.
• Comprehensive insight has been provided into the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Fuchs Endothelial Corneal Dystrophy (FECD) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• A detailed review of the Fuchs Endothelial Corneal Dystrophy (FECD) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Fuchs Endothelial Corneal Dystrophy (FECD) market.

Report Highlights

• In the coming years, the Fuchs Endothelial Corneal Dystrophy (FECD) market is set to change due to the rising awareness of the disease and the Favorable Environment for New Anti-infective Modalities; which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Fuchs Endothelial Corneal Dystrophy (FECD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Fuchs Endothelial Corneal Dystrophy (FECD). The launch of emerging therapies will significantly impact the Fuchs Endothelial Corneal Dystrophy (FECD) market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Fuchs Endothelial Corneal Dystrophy (FECD) Report Insights

• Patient Population
• Therapeutic Approaches
• Fuchs Endothelial Corneal Dystrophy (FECD)  Pipeline Analysis
• Fuchs Endothelial Corneal Dystrophy (FECD)  Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Fuchs Endothelial Corneal Dystrophy (FECD) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Fuchs Endothelial Corneal Dystrophy (FECD)  Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Fuchs Endothelial Corneal Dystrophy (FECD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Fuchs Endothelial Corneal Dystrophy (FECD) Market share (%) distribution in 2018, and how would it look like in 2030?
• What would be the Fuchs Endothelial Corneal Dystrophy (FECD) total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
• What are the key findings of the market across 7MM, and which country will have the largest Fuchs Endothelial Corneal Dystrophy (FECD) market Size during the forecast period (2018–2030)?
• At what CAGR, the Fuchs Endothelial Corneal Dystrophy (FECD) market is expected to grow in 7MM during the forecast period (2018–2030)?
• What would be the Fuchs Endothelial Corneal Dystrophy (FECD) market outlook across the 7MM during the forecast period (2018–2030)?
• What would be the Fuchs Endothelial Corneal Dystrophy (FECD) market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Fuchs Endothelial Corneal Dystrophy (FECD)?
• What is the historical Fuchs Endothelial Corneal Dystrophy (FECD)  patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Fuchs Endothelial Corneal Dystrophy (FECD)  in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Fuchs Endothelial Corneal Dystrophy (FECD)?
• Out of all 7MM countries, which country would have the largest prevalent population of Fuchs Endothelial Corneal Dystrophy (FECD) during the forecast period (2018–2030)?
• At what CAGR is the population expected to grow in 7MM during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Fuchs Endothelial Corneal Dystrophy (FECD) along with the approved therapy?
• What are the current treatment guidelines for treating Fuchs Endothelial Corneal Dystrophy (FECD) in the USA, Europe, and Japan?
• What are the Fuchs Endothelial Corneal Dystrophy (FECD)  marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Fuchs Endothelial Corneal Dystrophy (FECD)?
• How many therapies are developed by each company for the treatment of Fuchs Endothelial Corneal Dystrophy (FECD)?
• How many emerging therapies are in the mid-stage and late stages of development to treat Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Fuchs Endothelial Corneal Dystrophy (FECD) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fuchs Endothelial Corneal Dystrophy (FECD) and their status?
• What key designations have been granted for the emerging therapies for Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the global historical and forecasted market of Fuchs Endothelial Corneal Dystrophy (FECD)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Fuchs Endothelial Corneal Dystrophy (FECD) market.
• To understand the future market competition in the Fuchs Endothelial Corneal Dystrophy (FECD) market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Fuchs Endothelial Corneal Dystrophy (FECD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Fuchs Endothelial Corneal Dystrophy (FECD) market.
• To understand the future market competition in the Fuchs Endothelial Corneal Dystrophy (FECD) market.